Corpus Intelligence IC Memo — POINTE COUPEE GENERAL HOSPITAL 2026-04-26 11:19 UTC
IC Memo — POINTE COUPEE GENERAL HOSPITAL
Investment Committee Memorandum | LA | 23 beds | Grade D | EBITDA uplift $1.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

POINTE COUPEE GENERAL HOSPITAL

CCN 191316 | POINTE COUPEE PARISH, LA | 23 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

POINTE COUPEE GENERAL HOSPITAL is a 23-bed community hospital in POINTE COUPEE PARISH, LA with $16.0M in net patient revenue and a -20.9% operating margin. The hospital serves a payer mix of 40.6% Medicare, 0.0% Medicaid, and 59.4% commercial.

Thesis: Turnaround. Our ML models identify $1.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -20.9% to -13.5% (+736bps).

Net Revenue HCRIS$16.0M
Current EBITDA COMPUTED$-3.3M
Operating Margin COMPUTED-20.9%
Occupancy HCRIS14.4%
Revenue / Bed COMPUTED$694K
Net-to-Gross HCRIS50.7%
Distress Probability MLnan%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
125
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of -20.9% places it below the state median. Among 125 size-comparable peers (12-46 beds), the median margin is -2.3%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-46), prioritizing same-state peers. 125 hospitals in the comp set.

HospitalStateBedsRevenueMargin
POINTE COUPEE GENERAL HOSPITAL (Target)LA23$16.0M-20.9%
SPECIALISTS HOSPITAL OF SHREVELA15$79.1M21.3%
OCHSNER BAYOU LLCLA25$76.5M-0.9%
OUR LADY OF THE ANGELS HOSPITALA36$76.2M-4.9%
CENTRAL LOUISIANA SURGICAL HOSLA24$69.1M7.7%
ABBEVILLE GENERAL HOSPITALLA44$68.5M3.4%
ST. CHARLES PARISH HOSPITALLA27$64.0M-5.1%
AVALALA21$64.0M7.4%
BYRD REGIONAL HOSPITALLA39$61.1M2.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$335K+210bp18mo
Cost to Collect4.5%2.5%$319K+200bp12mo
Denial Rate Reduction12.0%6.5%$316K+198bp12mo
A/R Days Reduction5200.0%3800.0%$194K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$335K
Cost to Collect
$319K
Denial Rate Reduction
$316K
A/R Days Reduction
$194K
Clean Claim Rate
$10K
Total EBITDA Uplift$1.2M
Current EBITDA$-3.3M
+ RCM Uplift+$1.2M
Pro Forma EBITDA$-2.2M
Current Margin-20.9%
Pro Forma Margin-13.5%
WC Released (1x)$612K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-5.1M$-10.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-5.1M$-12.9M0.00x-100.0%
Bull Case9.0x11.0x$-4.6M$-10.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-4.6M$-13.0M0.00x-100.0%
Bear Case11.0x10.0x$-5.6M$-14.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-5.6M$-17.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 14.4%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 125 hospitals with 12-46 beds
  • Same-state prioritization (n=126)
  • Comp margins: P25=-14.3% / P50=-2.3% / P75=6.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.